Good guidance on dose reductions in patients on Venetoclax with severe hepatic impairment. Should help manage dose related adverse effects. @CllSociety @LumereHQ @RoswellPark #CLL #VENETOCLAX
RT @hemepa_c: Pharmacokinetics of venetoclax in patients with hepatic impairment - likely no dose adjustments required in mild or moderate,…
RT @hemepa_c: Pharmacokinetics of venetoclax in patients with hepatic impairment - likely no dose adjustments required in mild or moderate,…
RT @hemepa_c: Pharmacokinetics of venetoclax in patients with hepatic impairment - likely no dose adjustments required in mild or moderate,…
RT @hemepa_c: Pharmacokinetics of venetoclax in patients with hepatic impairment - likely no dose adjustments required in mild or moderate,…
Pharmacokinetics of venetoclax in patients with hepatic impairment - likely no dose adjustments required in mild or moderate, consider 50% dose reduction in those with severe: https://t.co/KR0dIBe8KK
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. #lymphoma #lymsm https://t.co/Zd3PfFlR5S